Sutro Biopharma Spotlights Next-Gen Cancer Drugs in London

SOUTH SAN FRANCISCO, CA – February 23, 2026 – As the global oncology community converges for the 16th World ADC London Summit, clinical-stage innovator Sutro Biopharma is taking a prominent position, signaling a concerted effort to showcase its advanced antibody-drug conjugate (ADC) platform. The company's participation, led by renowned ADC expert and Chief Scientific Officer Dr. Hans-Peter Gerber, is centered on its pioneering work in dual-payload ADCs, a technology poised to tackle one of modern oncology's greatest challenges: treatment resistance.

Over the next three days, Dr. Gerber is scheduled to participate in high-level panel discussions on investment and innovation before delivering a key presentation on the efficacy and safety of dual-payload ADCs. This strategic presence at one of the industry's most influential gatherings highlights Sutro's ambition to not only advance its own pipeline but also to help shape the future of targeted cancer therapy.

A Strategic Showcase in a Competitive Arena

The World ADC London Summit is more than a scientific conference; it is a critical marketplace for ideas, partnerships, and capital in a sector experiencing explosive growth. The global ADC market, valued at approximately $10 billion in 2023, is projected by analysts to surge to nearly $40 billion by 2030. This rapid expansion is fueled by a string of successful drug approvals and a deeper understanding of how to precisely deliver potent toxins to cancer cells while sparing healthy tissue.

In this high-stakes environment, Sutro's prominent role is a calculated strategic play. For a clinical-stage company, visibility at such an event is paramount for attracting the partnerships and investment necessary to navigate the costly path to commercialization. The landscape is dominated by pharmaceutical giants like AstraZeneca, Gilead, and Pfizer—which dramatically expanded its footprint with the $43 billion acquisition of ADC pioneer Seagen in 2023. For innovators like Sutro, a differentiated technology platform is the key to competing and collaborating.

The company's journey underscores the volatile nature of biotech deal-making. In April 2024, Sutro announced a licensing deal with Ipsen for its ROR1-targeting ADC, STRO-003, potentially worth up to $900 million. However, by August 2025, Ipsen had terminated the agreement following a strategic review, a stark reminder of the shifting priorities and immense pressures within the ROR1 drug development landscape. This experience, while a setback, also highlights the significant value proposition that Sutro's assets represent and the intense scrutiny applied to every new development in the field. The company's ongoing collaborations, including a partnership with Astellas on immunostimulatory ADCs (iADCs), have already generated substantial non-dilutive capital and demonstrate continued industry interest in its platform.

The Science of "Supercharged" Cancer Killers

At the heart of Sutro's strategy is its proprietary XpressCF® platform, a cell-free protein synthesis technology that offers an unparalleled level of precision in designing ADCs. Traditional ADCs, often described as "biological missiles," link a tumor-targeting antibody to a cytotoxic payload. While transformative, their effectiveness can be limited by tumor heterogeneity and the development of drug resistance.

Sutro is focusing on a next-generation solution: dual-payload ADCs. These complex molecules attach two different cancer-killing agents to a single antibody, enabling a multi-pronged attack on tumor cells. By using drugs with distinct mechanisms of action, this approach can potentially achieve a synergistic effect, prevent cancer cells from escaping treatment, and overcome resistance pathways that stymie single-payload therapies.

However, manufacturing these sophisticated drugs presents significant technical hurdles. Ensuring that each antibody carries the correct number and ratio of both payloads is critical for safety and efficacy. This is where the XpressCF® platform provides a crucial advantage. By building the ADC in a controlled, cell-free environment, Sutro can precisely engineer the placement of each linker and payload, resulting in a homogeneous product with a consistent drug-antibody ratio (DAR). This precision is vital for optimizing the therapeutic window—maximizing anti-tumor activity while minimizing off-target toxicity.

Dr. Gerber, who has contributed to the development of six of the 15 FDA-approved ADCs, will detail this approach in his presentation, "Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs." His deep expertise lends significant weight to Sutro's claims and provides a forum to discuss how this technology could create "supercharged ADCs" capable of delivering more durable responses for patients.

Advancing a Pipeline to Address Unmet Needs

Sutro's technology platform is not merely theoretical; it is the engine behind a maturing clinical pipeline aimed at cancers with limited treatment options. The company's most advanced candidate, luveltamab tazevibulin (Luvelta), a folate receptor alpha (FolRα)-targeting ADC, has undergone extensive study in platinum-resistant ovarian cancer, an area of high unmet need. While the company made a strategic decision in 2025 to defer further development in that specific indication to focus on its next-generation portfolio, the program provided valuable clinical data and experience.

The company's focus has now sharpened on newer assets. STRO-004, an ADC targeting Tissue Factor (TF) expressed on various solid tumors, entered Phase 1 trials in late 2025 and is now positioned as a lead program. Following it is STRO-006, targeting integrin β6 (ITGB6), which is slated to enter the clinic in 2026 for multiple solid tumors.

Most indicative of its future direction is the advancement of its first dual-payload candidate, STRO-227. This molecule targets PTK7, an antigen found on breast, lung, ovarian, and colorectal cancers, with an IND submission targeted for 2026 or 2027. This program, along with the iADC collaboration with Astellas, represents the tangible output of the company's long-term vision. By systematically building on its platform's unique capabilities, Sutro is creating a portfolio designed to address the next frontier in oncology. As these innovative therapies progress through clinical development, the industry will be watching closely to see if the precision engineering born in a cell-free system can translate into meaningful breakthroughs for patients fighting advanced cancer.